Cargando...

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Flinn, Ian W., Burger, Jan A., Tran, Anh, Clow, Fong, James, Danelle F., Graef, Thorsten, Friedberg, Jonathan W., Rai, Kanti, O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2015
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424415/
https://ncbi.nlm.nih.gov/pubmed/25755291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-585869
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!